Table 1.
Characteristics of elderly patients with high-grade astrocytoma
| Total | 65–69 years | 70–91 years | P value | ||
| Sex | Male | 51 | 10 | 41 | 0.46 |
| Female | 40 | 11 | 29 | ||
| Preop KPS | Median (range) | 60 (30-100) | 70 (40-100) | 60 (30-100) | |
| ≥70 | 41 | 12 | 29 | 0.22 | |
| ≤60 | 50 | 9 | 41 | ||
| Postop KPS | Median (range) | 60 (40-100) | 70 (50-100) | 60 (40-90) | |
| ≥70 | 33 | 11 | 22 | 0.12 | |
| ≤60 | 58 | 10 | 48 | ||
| Change in
perioperative KPS |
Increase or no
change |
53 | 12 | 41 | 1.00 |
| Decrease | 38 | 9 | 29 | ||
| CCI | 0 | 57 | 18 | 39 | 0.04 |
| 1 | 23 | 2 | 21 | ||
| 2 | 8 | 0 | 8 | ||
| 3 | 3 | 1 | 2 | ||
| ≥4 | 0 | 0 | 0 | ||
| EOR | Gross total removal | 16 | 7 | 9 | 0.01 |
| Partial removal | 35 | 10 | 25 | ||
| Biopsy | 40 | 4 | 36 | ||
| Pathology | Glioblastoma | 72 | 20 | 52 | 0.06 |
| Anaplastic
astrocytoma |
19 | 1 | 18 | ||
| IDH1 | Wild type | 55 | 14 | 41 | 0.16 |
| Mutation | 1 | 1 | 0 | ||
| No test | 35 | 6 | 29 | ||
| MGMT | Immunopositive
(≥10%) |
47 | 12 | 35 | 0.94 |
| Immunonegative
(<10%) |
30 | 6 | 24 | ||
| No test | 14 | 3 | 11 | ||
| Chemotherapy | Temozolomide | 64 | 19 | 45 | 0.10 |
| ACNU | 2 | 0 | 2 | ||
| None | 25 | 2 | 23 | ||
| Radiation dose | 60Gy | 52 | 19 | 33 | <0.001 |
| 40.05Gy | 32 | 1 | 31 | ||
| None | 7 | 1 | 6 | ||
| Adjuvant therapy | Chemoradiation | 62 | 19 | 41 | 0.015 |
| Others | 29 | 2 | 27 | ||
| Salvage therapy | Yes | 29 | 8 | 21 | 0.59 |
| No | 62 | 13 | 49 |
Abbreviations: KPS, Karnofsky Performance Status; CCI, Charlson comorbidity index; EOR, extent of resection; IDH1, isocitrate dehydrogenase 1; MGMT, O6-methylguanine-DNA methyltransferase; ACNU, 1-(4-amino-2-methyl-5-pyrimidinyl)-methyl-3-(2-cholroethyl)-3-nitrosourea hydrochloride